Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE7.3700
- TODAY'S CHANGE (%)-0.0400 (-0.5398%)
- Bid / Lots7.2200/ 15
- Ask / Lots7.5300/ 11
- Open / Previous Close7.4300 / 7.4100
- Day Range
- 52 Week Range
- Volume28,871
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 137 | 7.43 |
| 09:33 ET | 207 | 7.4468 |
| 09:55 ET | 973 | 7.45 |
| 10:27 ET | 441 | 7.4 |
| 11:03 ET | 100 | 7.4 |
| 11:09 ET | 236 | 7.4 |
| 11:23 ET | 874 | 7.31 |
| 11:43 ET | 1500 | 7.285 |
| 11:45 ET | 100 | 7.27 |
| 11:48 ET | 100 | 7.3026 |
| 11:50 ET | 200 | 7.31 |
| 12:03 ET | 100 | 7.35 |
| 12:15 ET | 100 | 7.34 |
| 12:33 ET | 100 | 7.335 |
| 12:46 ET | 800 | 7.31 |
| 01:27 ET | 100 | 7.38 |
| 01:38 ET | 200 | 7.4199 |
| 01:44 ET | 200 | 7.4348 |
| 01:47 ET | 100 | 7.405 |
| 01:51 ET | 1850 | 7.38 |
| 02:21 ET | 156 | 7.38 |
| 02:30 ET | 100 | 7.38 |
| 02:45 ET | 5891 | 7.35 |
| 02:54 ET | 150 | 7.365 |
| 03:06 ET | 200 | 7.3201 |
| 03:15 ET | 222 | 7.35 |
| 03:30 ET | 6673 | 7.365 |
| 03:42 ET | 410 | 7.41 |
| 03:44 ET | 501 | 7.34 |
| 03:50 ET | 100 | 7.335 |
| 03:51 ET | 1500 | 7.365 |
| 04:00 ET | 859 | 7.37 |
Nov 5, 2024
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR), from 10:58AM ET on Tuesday Nov 05, 2024 by Dow Jones
10:58AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 28, 2024
*DJ Kezar Life Sciences Announces 1-for-10 Reverse Stock Split >KZR, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow JonesKezar Life Sciences Announces 1-for-10 Reverse Stock Split, from 8:30AM ET on Monday Oct 28, 2024 by Dow Jones
8:30AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 17, 2024
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan, from 8:35AM ET on Thursday Oct 17, 2024 by Dow Jones
8:35AM ET on Thursday Oct 17, 2024 by Dow JonesPress Release: Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan, from 8:35AM ET on Thursday Oct 17, 2024 by Dow Jones
8:35AM ET on Thursday Oct 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 537.7M | -0.5x | --- |
Verve Therapeutics Inc | 534.2M | -2.6x | --- |
Q32 Bio Inc | 546.2M | -2.8x | --- |
Aura Biosciences Inc | 539.7M | -6.1x | --- |
MeiraGTx Holdings PLC | 534.1M | -4.6x | --- |
Altimmune Inc | 545.8M | -4.7x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Chief Executive Officer, Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $537.7M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.24 |
EPS | $-13.55 |
Book Value | $25.77 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 76.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,531.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
